

Infantile Spasms Treated with Intravenous Methylprednisolone Pulse

How to Cite This Article: Hassanzadeh Rad A, Aminzadeh V. Infantile Spasms Treated with Intravenous Methylprednisolone Pulse. *Iran J Child Neurol.* Spring 2017; 11(2):8-12.

Afagh HASSANZADEH RAD Msc¹

Vahid AMINZADEH MD¹

1. Pediatrics Growth Disorders
Research Center, School of Medicine,
17th Shahrivar Hospital, Guilan
University of Medical Sciences, Rasht,
Iran

Corresponding Author:
Aminzadeh V. MD
Pediatric Growth Disorder Research
Center, 17 Shahrivar Hospital, Shahid
Siadati St, Rasht, Iran.
Tel: +98-01333369002;
Mobile: +98-9122069314
Fax: +98-013133369061;
Email: AMINZADEH145@yahoo.com

Revised: 10-Sep-2015
Last Revised: 31-May-2016
Accepted: 9-Jul-2016

Abstract

Objective

Infantile spasms is diagnosed late even by expert pediatricians. Late diagnosis (later than 3 weeks) can have a negative effect on the long-term prognosis. We aimed to investigate infantile spasms treated with intravenous methylprednisolone pulse.

Materials & Methods

In this case series study, 20 infants with infantile spasms in 17-Shahrivar Hospital, Rasht, Iran were enrolled. Drugs were administered based on Mytinger protocol that included 3 days of methylprednisolone pulse and 56 days of oral prednisolone. The control of spasms and the omission of hypsarrhythmia in infants follow-up were the primary and secondary outcomes, respectively. Remission was indicated if the caregivers mentioned no spasms or >50% decrease regarding drug initiation for at least 5 consecutive days and the electroencephalography during sleep period noted the omission of hypsarrhythmia.

Results

Eleven female (55%) and 9 male (45%) patients with the mean age of 4.95 ± 1.39 months were enrolled. Mean rapid remission was noted as 4.41 ± 1.50 days. Twelve patients (60%) noted early remission. seizure was controlled in 3(15%) patients completely after 24 months. Five (25%) occasional seizures were noted controlled by routine anticonvulsant drugs after 24 months and 12 (60%) no response was mentioned. Most of the patients (65%) had cryptogenic etiology for infantile spasms. Uncontrolled seizure was mentioned after initial remission.

Conclusion

Methyl prednisolone is an appropriate drug based on easy administering, low cost, and its accessibility.

Keywords: Infantile spasms; Prednisolone; Administration; Intravenous

Introduction

Infantile spasms (IS) is an age-dependent myoclonic seizure that occurs in 25 per 100000 live births. Its etiology can't be defined in 75% of patients with infantile spasms. It usually initiates in 4-8 months after birth (the peak: 4-7 months) and always before 1 year of age (1).

According to the international league against epilepsy, infantile spasms are classified into symptomatic and cryptogenic types. Commonly, there is a sign of previous brain injury or a related to a specific etiology in symptomatic type. However, in cryptogenic

type, no sign of brain injury or specific etiology can be noted. As infantile spasms is a medical emergency, early diagnosis especially for cryptogenic type is mandatory (2). Generally, infantile spasms diagnoses late even by expert pediatricians and late diagnosis (later than 3 wk) can have a negative effect on the long-term prognosis (3). It is generally distinguished with common infantile disorders such as infantile colic. Electroencephalography is the most important method of diagnosis of infantile spasms showed by hypsarrhythmia. (1)

Although the ultimate development of infants depends on the cause but most of them encounter with diverse types of seizures and psychomotor retardation (4).

There is no specific treatment preferred in contrast with other types of treatment (5). American Academy of Neurology and pediatrics neurology society mentioned that there is no document that successful treatment can affect late prognosis. ACTH can be noted as a short-term treatment for infantile spasms, and vigabatrin can be effective (2). Although, ACTH is the traditional treatment of IS, however, oral prednisolone with the dosage of 2-4 mg/ kg/d for 8 wk can be an alternative method (1). Generally, 25%-33% of recurrence occurs after any type of treatment (6). Although, the preference of ACTH was reported on prednisolone but that can be effective when no response is reported by administering ACTH and vice versa (7).

Worldwide, ACTH is an expensive drug with a low access (scarce access), therefore, according to safety, cheap and easily accessible of intravenous methylprednisolone (8, 9), we aimed to investigate the effect of intravenous methylprednisolone pulse on the infantile spasms in patients hospitalized in 17-Shahrivar Hospital, Rasht, Iran

Materials & Methods

This observational case series study was conducted on 20 infants with IS hospitalized in 17 Shahrivar Hospital, Rasht, Iran during 2011-2014. Infants aged less than 1 year and more than 1 month with any etiology of spasms except tuberous sclerosis (vigabatrin is their choice treatment) (3), symptom of spasms and Hypsarrhythmia in EEG were included. Patients with kidney disease, hypertension, cardiac disease, and febrile or infectious diseases were excluded.

Consent letters were obtained from parents and the study was approved by Ethics Committee of the hospital.

Spasms were classified into cryptogenic and symptomatic types based on history, physical exam, brain MRI, and metabolic study. Patients were hospitalized in Neurology Ward to treat with methylprednisolone pulse. Vital signs were checked and parents were educated. In addition, fasting blood sugar, blood pressure and urine analysis and culture were monitored. Drugs were administered based on Mytinger protocol that included 3 days of methylprednisolone pulse and 56 days of oral prednisolone (Table 1) (10).

Primary outcome was the control of spasms and the second outcome was the omission of hypsarrhythmia in infants follow-up. Although prolonged video EEG is the most appropriate method for defining response but if there is no access, clinicians can consider routine EEG as well. Response was indicated if the caregivers mentioned no spasms or >50 % decrease regarding drug initiation for at least 5 consecutive days and the EEG during sleep period noted the omission of hypesarythmia (6). The minimum period of response was 2 wk (6, 10). The mentioned protocol will be used as a first treatment or will be added to the previous ineffective drugs with no change in the previous dosage of drugs (11).

Patients were followed up for 24 months after treatment. Data were gathered by a form including age, sex, etiology, previous treatment, period of spasms control, follow-up, EEG, and complications. Data were reported by number, percent, mean and standard deviation by SPSS software version 19.0 (Chicago, IL, USA).

Results

Eleven female (55%) and 9 male (45%) patients with the mean age of 4.95 ± 1.39 months participated in this study. Mean rapid remission was noted as 4.41 ± 1.50 days. Twelve patients (60%) noted that early remission. Seizure was controlled in 3 (15%) patients completely after 24 months. Five (25%) occasional seizures were noted controlled by routine anticonvulsant drugs after 24 months and 12 (60%) no response was mentioned. At the follow-up EEG, 13 patients (65%) were normal and 7 (35%) abnormal cases were noted. Most of the patients (65%) had cryptogenic etiology for infantile spasms. Seven (35%) repeated seizures, 5 (25%)

occasional seizures, 2 (10%) refractory seizures and 3 (15%) uncontrolled seizure were mentioned after initial remission. Besides, no seizure was noted in 3 (15%) patients after initial remission. Seven patients (35%) received only methylprednisone and methylprednisolone was added to previous drugs in 13 patients. No complication was noted in most of the patients (13 cases). However, 5-weight gain, one asymptomatic glucosuria, and 1 irritability were noted in patients with infantile spasms (Table 2).

Discussion

According to results, 60% of patients noted remission which was consistent with Mytinger et al. They also indicated 50% remission after administering pulse methyl prednisolone.(10) Azam et al compared remission by administering ACTH (33 patients)and oral prednisolone(72 patients) in 105 infants with infantile spasms. They mentioned improvement in 27 patients who received ACTH. From these 27 patients, 11 remained spasm free. 51 patients in oral prednisolone group responded and 17 remained spasm free after cessation the drug. Also, administering high dose oral prednisolone in patients with infantile spasms indicated 67% spasm free during 2 weeks. (11)LUX et al reported 54%, 76%, and 73% improvement by administering vigabatrin, ACTH and oral prednisolone in 208 patients with infantile spasms. (12)

In this study mean rapid remission was mentioned as 4.41±1.50 days which was similar with previous investigation. They noted rapid remission in 2-6 days. (10).

At the follow up, 13 patients(65%) were normal and 7

(35%)abnormal cases were noted. However, Mytinger et al noted lower rate of normal results(50%)(10)

Although our results indicated no complication in most of the patients by administering pulse methylprednisolone. But Mytinger et al indicated asymptomatic hypertension and probable adrenal insufficiency in patients treated with pulse methyl prednisolone. LUX et al noted 19 complications including gastrointestinal complication, irritability, drowsiness, infection, increased appetite, dermatological complication, mood disturbance, and neuropsychiatric disorders by administering oral prednisolone. However, they noted lower complications by administering ACTH and vigabatrin. (12) Kossoff et al noted 53% complications in patients received oral prednisolone including irritability, edema, weight gain and hypertension. (13)

As clinicians hospitalize patients for a short period of time (3 days) to administer pulse methyl prednisolone and during hospitalization, short term Complications of the pulse can be detected directly by clinicians and parents can be completely educated for follow up; Investigators proffered it versus oral type. Also, patients hospitalized can be better evaluated before treatment especially for asymptomatic infections and emergently clinicians can manage probable complications, it seems that Pulse methyl prednisolone can be recommended as a choice of treatment. Regarding similar effects of pulse methyl prednisolone in comparison with ACTH, it seems that methyl prednisolone is a preferable drug regarding easy administering, low cost and its accessibility.

Author`s Contribution

Hassanzadeh Rad A: Interpretation of data for the work,

Table 1. Protocol for intravenous methylprednisolone with oral prednisolone

Medication	Time period	Dose (mg/kg)
Intravenous methylprednisolone	Day 1-3	20/day
Oral prednisolone	Day 4-17 (2 wk)	4/day
	Day 18-31 (2 wk)	3/day
	Day 32-45 (2 wk)	2/day
	Day 46-52 (1 week)	2/every other day
	Day 53-59 (1 week)	1/every other day

Table 2. Patient Characteristics and Outcomes

num	Age (months)	sex	Etiology	Interval Between onset of spasms and treatment (day)	Early remission (day)	Follow up EEG	treatment	Late remission	complication
1	3	F	Cryptogenic	5	3	Abnormal (hypsarrythmia)	MP ¹	No seizure	Weight gain
2	4	M	Congenital CMV	15	No response	Normal	MP+PB ² +NZP	Uncontrolled seizure	Irritability
3	5	F	PKU	21	2	Abnormal	MP+TPM+PB	Occasional seizure	-
4	7	M	Cryptogenic	60	No response	Normal	MP+PB+CZP ³	Uncontrolled seizure	-
5	4	F	Structural	12	4	Normal	MP	Occasional seizure	-
6	3	F	Cryptogenic	8	6	Normal	MP+PB+CLB ⁴	No seizure	Weight gain
7	6	F	Cryptogenic	30	No response	Abnormal	MP+PB	Repeater seizure	-
8	5	M	Hypoxic ischemic encephalopathy	12	No response	Normal	MP+CZP ⁵ +PB	Repeated seizure	-
9	3	F	Cryptogenic	8	5	Normal	MP+PB+NZP ⁶	No seizure	Weight gain
10	5.5	M	Cryptogenic	17	3	Normal	MP+PB+NZP	Occasional seizure	-
11	5	M	Cryptogenic	14	5	Abnormal	MP+PB+TPM ⁷	Occasional seizure	Weight gain
12	6.5	M	Structural	20	No response	Normal	MP	Refractory seizure	-
13	3.5	F	CMV	10	4	Normal	MP+PB+TPM+LTG ⁸	Occasional seizure	-
14	5	M	Cryptogenic	10	3	Abnormal	MP+PB+CZP	Repeated seizure	-
15	8	F	Cryptogenic	60	No response	Normal	MP	Refractory seizure	Asymptomatic glucosuria
16	5	M	Cryptogenic	12	6	Normal	MP+PB+TPM	Repeated seizure	-
17	4.5	F	Down syndrome	17	5	Abnormal	MP+PB+NZP	Repeated seizure	-
18	7	M	Cryptogenic	21	No response	Normal	MP	Repeated seizure	Weight gain
19	5	M	structural	15	7	Normal	MP	Repeated seizure	-
20	5	F	Cryptogenic	10	No response	Normal	MP+CZP+LTG	Repeated seizure	-

¹MP:Methylprednisolone, ²PB: Phenobarbital, ³CZP: Certolizumab pegol, ⁴CLB: Clobazam, ⁵CZP: Clonazepam, ⁶NZP:Nitrazepam, ⁷TPM:Topiramate, ⁸LTG:Lamotrigine

drafting the work or revising it critically for important intellectual content, Final approval of the version to be published, Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Aminzadeh V: Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work, drafting

the work or revising it critically for important intellectual content, Final approval of the version to be published, Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Conflict of interest

The authors declare that there is no conflict of interest.

References

1. Widjaja E, Go C, McCoy B, Snead OC. Neurodevelopmental outcome of infantile spasms: a systematic review and meta-analysis. *Epilepsy Res* 2015;109:155-62.
2. Mackay M, Weiss S, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill K, et al. Practice Parameter: Medical Treatment of Infantile Spasms Report of the American Academy of Neurology and the Child Neurology Society. *Neurology* 2004;62(10):1668-81.
3. Abbas A, Elseed M, Hamed A, Mohamed IN. The role of oral prednisolone in the management of infantile spasms in resource-limited countries: experience from Sudan. *Khartoum Med J* 2016 Apr 5;7(3): 1012-18.
4. Riikonen R. A long-term follow-up study of 214 children with the syndrome of infantile spasms. *Neuropediatrics* 1982;13(1):14-23.
5. O'Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. *The Lancet Neurol* 2017;16:33-42.
6. Pellock JM, Hrachovy R, Shinnar S, Baram TZ, Bettis D, Dlugos DJ, et al. Infantile spasms: a US consensus report. *Epilepsia* 2010;51(10):2175-89.
7. Hrachovy RA, Frost JD, Kellaway P, Zion TE. Double-blind study of ACTH vs. prednisone therapy in infantile spasms. *J Pediatr* 1983;103(4):641-5.
8. Delesalle F, Staumont D, Houmany MA, Breviere GM, Piette F. Pulse methylprednisolone therapy for threatening periocular haemangiomas of infancy. *Acta Derm Venereol* 2006;86(5):429-32.
9. Nguyen J, Fay A. Pharmacologic therapy for periocular infantile hemangiomas: a review of the literature. *Semin Ophthalmol* 2009; 24(3):178-184.
10. Mytinger JR, Quigg M, Taft WC, Buck ML, Rust RS. Outcomes in treatment of infantile spasms with pulse methylprednisolone. *J Child Neurol* 2010; 25(8): 948-53.
11. Azam M, Bhatti N, Krishin J. Use of ACTH and prednisolone in infantile spasms: experience from a developing country. *Seizure* 2005;14(8):552-6.
12. Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. *The Lancet* 2004;364(9447):1773-8.
13. Kossoff EH, Hartman AL, Rubenstein JE, Vining EP. High-dose oral prednisolone for infantile spasms: an effective and less expensive alternative to ACTH. *Epilepsy Behav* 2009;14(4):674-6.